

INTENDED USE

The SPIFE Nexus Split Beta SPE method is intended to quantitatively determine the presence of normal and abnormal serum proteins and qualitatively determine the presence of urine proteins by agarose electrophoresis using the SPIFE Nexus System.

For *In Vitro* Diagnostic Use Only.

Rx Only

SUMMARY

Serum contains over one hundred individual proteins, with specific functions and various concentrations under different pathologic conditions.¹ Since introduction of moving-boundary electrophoresis by Tiselius² and the subsequent use of zone electrophoresis, serum proteins have been fractionated on the basis of their electrical charge at a particular pH into five classical fractions: albumin, alpha₁, alpha₂, beta and gamma proteins. Each of these classical electrophoretic zones, with the exception of albumin, normally contains two or more components. Knowing the relative proportions of these fractions has proven useful in the diagnosis and prognosis of certain disease states.^{3,4,5}

PRINCIPLE

Proteins are large molecules composed of covalently linked amino acids. Depending on electron distributions resulting from covalent or ionic bonding of structural subgroups, proteins can be either polar or nonpolar at a given pH. Proteins are separated according to their respective electrical charges on agarose gel using both the electrophoretic and electroendosmotic forces present in the system. The proteins are then stained with a visible stain.

REAGENTS

1. SPIFE Split Beta SPE Gel

Ingredients: Each gel contains agarose in a tris-barbital/MOPS buffer with calcium lactate, a stabilizer, and a preservative.

WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. The gel contains barbital which, in sufficient quantity, can be toxic.

Preparation for Use: The gels are ready for use as packaged.

Storage and Stability: The gels should be stored at room temperature (15 to 30°C) and are stable until the expiration date indicated on the package. The gels must be stored horizontally in the protective packaging in which they are shipped. **DO NOT REFRIGERATE OR FREEZE THE GELS.** Avoid storage close to a window or heat source, and avoid temperature variation during storage.

Signs of Deterioration: Any of the following conditions may indicate deterioration of the gel: (1) crystalline appearance indicating the agarose has been frozen, (2) cracking and peeling indicating drying of the agarose, (3) bacterial growth indicating contamination, (4) thinning of the gel blocks.

2. SPIFE Nexus Blue

Ingredients: The stain contains 0.5% (w/v) acid blue stain, 5% acetic acid, and surfactant.

WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. DO NOT INGEST.

Preparation for Use: The stain is ready for use as packaged.

Storage and Stability: The stain solution is stable for one year when stored at 15 to 30°C in a closed container.

Signs of Deterioration: The prepared stain should be a homogeneous mixture free of precipitate. Discard if precipitate forms.

3. Citric Acid Destain

Ingredients: After dissolution, destain contains 0.3% (w/v) citric acid.

WARNING: FOR IN-VITRO DIAGNOSTIC USE. DO NOT INGEST - IRRITANT.

Preparation for Use: Pour 11 L of deionized water into Destain vat. Add full package of Destain and mix until completely dissolved.

Storage and Stability: Store the Destain at 15 to 30°C. It is stable until the expiration date on the package.

Signs of Deterioration: Discard if solution becomes cloudy.

4. SPIFE Nexus Violet (Optional Urine Stain)

Ingredients: Contains 0.2% (w/v) acid violet stain and 10% acetic acid.

WARNING: FOR IN-VITRO DIAGNOSTIC USE ONLY. DO NOT INGEST.

Preparation for Use: The stain is ready for use as packaged.

Storage and Stability: The stain solution is stable for one year when stored at 15 to 30°C in a closed container.

Signs of Deterioration: The stain should be a homogeneous mixture free of precipitate.

INSTRUMENT

A SPIFE Nexus analyzer must be used to apply samples, electrophorese, stain, destain, dry and then scan the gels. The gels may also be scanned on a separate densitometer such as the QuickScan Touch Plus (Cat. No. 1640). Refer to the Operator's Manuals for detailed instructions.

SPECIMEN COLLECTION AND HANDLING

Specimen: Fresh serum or urine is the specimen of choice. Use of plasma will cause a fibrinogen band to appear as a distinct narrow band between the beta and gamma fractions.

Storage and Stability: If storage is necessary, store serum samples covered at 15 to 30°C for 4 days, 2 to 8°C for 2 weeks or -20°C for 6 months.⁶ Urine samples may be stored at 2 to 8°C for up to 72 hours or at -20°C for 1 month.

Urine Sample Preparation: Urine samples may be run diluted, neat or concentrated. Urines should be concentrated if a higher sensitivity is desired. Shake samples to homogenize. Centrifuge desired volume at 2000 x g for 5 minutes. Remove supernatant and concentrate as follows:

Total Protein (mg/dL)	Conc. Factor
<50	100x
50-100	50x
100-300	25x
300-600	10x
>600	5x

Interfering Factors:

1. Hemolysis may cause false elevation in the alpha₂ and beta fractions.
2. Uncovered specimens may yield inaccurate results due to evaporation.

PROCEDURE

Materials provided: The following materials needed for the procedure are contained in the SPIFE Nexus Split Beta SPE Kit. Individual items are not available.

Test Size	Cat. No.
80 Samples	2399
100 Samples	2398
Cat. No. 2398, 2399	
SPIFE Split Beta SPE Gels (10)	
SPIFE Nexus Blue (1 vial)	
SPIFE Blotter C (10)	
Citric Acid Destain (1 pkg)	
Serrated Blade Applicator Kit, 20 Sample (40/50)	

Materials provided but not contained in the kit:

Item	Cat. No.
SPIFE Nexus Analyzer	1650
QuickScan Touch Plus	1640
Gel Block Remover	1115
SPE Normal Control	3424
SPE Abnormal Control	3425
SPIFE Dispo Sample Cups, Deep Well	3360
SPIFE 80, 100 Dispo Cup Tray	3366
SPIFE Nexus Cassette	2580
SPIFE Nexus Applicator Templates	2570
SPIFE Nexus Applicator Blade Weights	2572
SPIFE Nexus Dispo Stain Cups	2575
Pos ID Barcode Labels for Touch & SPIFE Nexus Systems	1696
REP Prep	3100
SPIFE Nexus Reagent Roller	2583
SPIFE Nexus Ready Run Kit	2582
SPIFE Nexus Carbon Electrode Insert	2576
SPIFE Nexus Violet	552683

Materials needed but not provided:

0.85% saline

STEP-BY-STEP METHOD

I. Sample Preparation

Serum: No specimen preparation is necessary for serum. Serum samples will be automatically pipetted into sample cups at a volume of 80 µL per sample.

Urine: Urine specimens cannot be run on the same gel with serum samples due to differences in the running parameters. Urine samples may be concentrated if desired. Urine samples or concentrations will be automatically pipetted into sample cups at a volume of 80 µL per sample. For urine specimen volumes measuring less than 500 µL, contact Technical Service for instructions on manual loading.

II. SPIFE Nexus Preparation

- Fill designated bottles with 0.85% saline, deionized water, and destain.
- Turn on the SPIFE Nexus. Click on the SPIFE Nexus icon to initialize.
- If this is the first test of the day, prime the instrument according to the instructions in the SPIFE Nexus Operator's Manual.
- Load the correct number of uncapped patient sample test tubes into test tube racks and place racks within the tube transport area.
- Open the main door and prepare the items onboard the instrument.
 - Ensure that the following items are in their respective onboard storage locations: **Platen Cover** with the Carbon Electrode Insert and **Dryer Cover** with the red sticker toward the back of the instrument.
- Sample Cup Tray**
 - Prepare the sample cup tray with the appropriate disposable deep well sample cups. Slide the Disposable Sample Cups into the cup tray. Use only the top four rows for 80 or fewer samples, and all five rows for up to 100 samples.
 - Place the cup tray onto the sample tray platform.
- Stain/Reagent Dispenser**
 - Fill three Stain Cups each with 700 µL of SPIFE Nexus Blue stain and place a Stain Cup in each slot of the Stain/Reagent Dispenser. **NOTE: As an optional urine stain, SPIFE Nexus Violet may be substituted for SPIFE Nexus Blue.**
 - Place a clean Reagent Roller bar between the hooks on the Stain/Reagent Dispenser.

4. Consumables Tray

- Slide the Consumables Tray forward from its home position.
- Prepare the Applicator Holder
 - Place a Split Beta (100) Applicator Template on top of the Applicator Holder. Place Applicator Blades in the designated slots corresponding to the sample cups loaded within the sample tray. **NOTE: The Applicator Blades will only fit into the slots in the Applicator Holder one way; do not try to force the Applicator Blades into the slots.**
 - Place the Applicator Blade Weights on top of the Applicator Blades with the thick side facing the front of the instrument.
- Slide the Consumables Tray into position in the back of the instrument.

5. Gel Cassette

- Place the bottom half of the Gel Cassette on the electrophoresis platen with the two pins lined up on the left side.
- Dispense 2 mL of REP Prep on the platen.
- Remove the gel from the protective packaging and discard the overlay.
- Using a SPIFE Blotter C, gently blot the entire gel. Discard the blotter.
- Place the left edge of the gel into the bottom of the cassette fitting the round hole over the upper pin and the obround hole over the lower pin. Gently lay the gel down over the REP Prep making sure no bubbles remain under the gel.
- Place the top half of the Gel Cassette over the gel. Make sure the 2D barcode is located in the upper right corner of the cassette.
- Place a Positive ID Barcode Label on the upper right hand side of the gel backing. Select the barcode that starts with the letter "G".

F. Close the main door of the instrument.

III. Automated Gel Electrophoresis

- Click the Start button on the menu bar. Select the **SPIFE Split Beta Serum Proteins 100 (Acid Blue)**, **SPIFE Urine Proteins 100 (Acid Blue)** or **SPIFE Urine Proteins 100 (Acid Violet)** test name from the drop down menu. Ensure the toggles for all Run Processes are set to "Yes" and click the Start Run button. The analyzer will load samples when appropriate, apply samples, electrophoresis, stain, destain, dry and scan the gel. For details of Automated Gel Electrophoresis parameters, contact Technical Services.
- After scanning, the Gel Cassette with the finished gel will be located in the scanner port on the front side of the instrument. If gel storage is required, remove and discard the two gel blocks.
- After every test: discard the used blotters, Applicator Blades, Stain Cups and sample cups as biohazardous waste. Clean any residual stain from the electrophoresis platen, Gel Cassette and the Reagent Roller bar. For daily, weekly, and monthly maintenance, reference the SPIFE Nexus Operator's Manual.

Evaluation of the Protein Bands

Quantitative Evaluation of Serum: The SPIFE Nexus Split Beta SPE Gel will be automatically scanned. An aperture size of 5 with the acid blue setting is recommended. Refer to the QuickScan Touch Plus Operator's Manual for scanning parameters.

Qualitative Evaluation of Urine: The urine samples run on the SPIFE Nexus Split Beta SPE Gel can only be visually inspected for the presence of the bands.

Stability of End Product: The completed, dried SPIFE Split Beta SPE Gel is stable for an indefinite period of time.

Quality Control: SPE Normal Control (Cat. No. 3424) and SPE Abnormal Control (Cat. No. 3425) may be used to verify all phases of the procedure and should be used on each gel run. If desired, a control or patient sample may be diluted 1:7 with 0.85% saline (1 part sample + 6 parts saline) and run with urines for qualitative comparison. Refer to the package insert provided with the control for assay values.

REFERENCE VALUES

The reference ranges presented were established with the Split Beta SPE System on 40 normal specimens using the SPIFE Nexus. These values are presented as a guideline.

Protein Fraction	% of Total Mean \pm 2 S.D.
Albumin	47.3 - 62.7
Alpha ₁	1.8 - 4.3
Alpha ₂	7.3 - 14.4
Beta	13.5 - 19.7
Gamma	6.5 - 22.5

Each laboratory should perform its own normal range study.

Variations of Expected Values⁵

Studies show that values are the same for both males and non-pregnant females (Some differences are seen in pregnant females at term and in women on oral contraceptives).

Age has some effect on normal levels. Cord blood has decreased total protein, albumin, alpha₂ and beta fractions, slightly increased alpha₁ and normal or increased gamma fractions (largely of maternal origin). The gamma globulins drop rapidly until about three months of age, while the other fractions have reached adult levels by this time. Adult levels of the gamma globulins are not reached until 16 years of age. The albumin decreases and beta globulin increases after the age of 40.

RESULTS

Figure 1 illustrates the electrophoretic mobilities of the albumin, alpha₁, alpha₂, beta and gamma protein bands on a SPIFE Split Beta SPE Gel. The fastest moving band, and normally the most prominent, is the albumin band found closest to the anodic edge of the gel. The faint band next to this is alpha₁, followed by alpha₂ globulin, split beta and gamma globulins.




Figure 1: A SPIFE Split Beta SPE-100 Gel showing relative position of the bands.




Figure 2: A scan of a SPIFE Split Beta SPE pattern.

Calculations of the Unknown

The SPIFE Nexus scanner will automatically calculate and print the relative percent and the absolute value of each band when the total protein is entered. Refer to the SPIFE Nexus and QuickScan Touch Plus Operator's Manuals provided with the instrument.

INTERPRETATION OF RESULTS^{5,6}

Results on normal individuals will cover age and sex-related variations and day-to-day biologic variations. Disease states in which abnormal patterns are observed include inflammatory response, rheumatic disease, liver diseases, protein-loss disorders, plasma cell dyscrasias, infectious disorders, renal disorders, pregnancy, and genetic deficiencies. Patients with high levels of IgG4 can produce a relatively restricted band cathodic in the beta gamma region or beta gamma bridging.⁷ Proteins migrating in the alpha₂ and beta region may show slight variation in migration under a variety of circumstances.⁸

Further Testing Required

The serum or urine protein electropherogram, or densitometric tracing, should be evaluated for abnormalities. If abnormalities are observed, appropriate follow-up studies should be initiated.⁹ Not all clinically significant monoclonal gammopathies will display a distinct band detectable by protein electrophoresis.¹⁰ Further studies may be indicated based on clinical context. These may include immunofixation, quantitation of immunoglobulins, bone marrow examination and other appropriate tests.

LIMITATIONS

1. Since all electrophoretic procedures are nonlinear, it is critical to fill the wells with the recommended volume of serum or urine to obtain optimal resolution and reproducible results. Noncompliance with the recommended procedure may affect the results.
2. Therapeutic monoclonal antibodies may be used in the treatment of multiple myeloma as well as various other malignancies or medical conditions. If present in sufficient concentration, these agents may be indistinguishable from a pathologic monoclonal protein on serum protein electrophoresis.^{11,12}
3. Use of plasma will cause a fibrinogen band to appear as a distinct narrow band between the beta and gamma fractions. A fibrinogen band may also be present in patients on heparin therapy.
4. Hemolyzed samples should be avoided as changes in hemoglobin-haptoglobin may affect the alpha₂ and beta migration.^{13,14}
5. The mobility of beta lipoprotein (low density lipoprotein) can vary considerably and may migrate under normal conditions anywhere between the alpha₂ and beta region. Beta lipoproteins can be recognized by their characteristic appearance as a thin, irregular line, regardless of its migration location.
6. An artifact may be present at the point of application, particularly with the use of frozen samples, older samples, or samples containing debris.¹³ An application artifact may appear as fine clear line (negative space) that may be visible to a faint degree across the entire gel in the beta region. This can on occasion cause the edge of a normal blush to appear slightly blunted.

SPECIFIC PERFORMANCE CHARACTERISTICS

Reproducibility was assessed over a 5 day period. Normal and abnormal serum controls were tested on two gels per day on each of three SPIFE Nexus instruments. Three hundred sixty determinations per protein fraction in total were collected for the normal and abnormal serum protein controls respectively.

Normal Control Fraction	N	Mean %	Within Day		Between Day		Between Instrument		Total	
			SD	CV%	SD	CV%	SD	CV%	SD	CV%
Albumin	300	57.0	2.45	4.3	0.56	0.98	2.51	4.41	2.69	4.72
Alpha ₁	300	3.7	0.31	8.41	0.004	0.10	0.31	8.41	0.34	9.16
Alpha ₂	300	10.9	0.97	8.9	0.92	8.47	1.34	12.28	1.35	12.34
Beta	300	15.5	1.23	7.94	0.84	5.41	1.49	9.61	1.49	9.64
Gamma	300	12.9	1.63	12.64	0.43	3.32	1.69	13.08	1.73	13.44

Normal Control Fraction	N	Mean %	Within Day		Between Day		Between Instrument		Total	
			SD	CV%	SD	CV%	SD	CV%	SD	CV%
Albumin	300	54.5	2.33	4.28	0.62	1.14	2.41	4.43	2.63	4.82
Alpha ₁	300	3.2	0.28	8.63	0.04	1.2	0.28	8.71	0.30	9.42
Alpha ₂	300	8.7	0.59	6.8	0.13	1.52	0.61	6.96	0.65	7.45
Beta	300	12.0	0.78	6.49	0.14	1.16	0.79	6.59	0.86	7.13
Gamma	300	21.7	1.55	7.13	0.45	2.09	1.61	7.43	1.68	7.72

SENSITIVITY

A pathological serum sample with a monoclonal protein at 1.76 g/dL (1760 mg/dL) was serially diluted and the dilutions electrophoresed on the SPIFE Split Beta SPE gel on the SPIFE Nexus. After visual inspection and densitometric analysis of the gel, the lowest detectable concentration of a monoclonal protein was between 0.014 and 0.028 g/L (14 and 28 mg/dL).

NOTE: The migration position of the monoclonal protein and the presence of a polyclonal background in the gamma zone may affect the detection limit.

CORRELATION

Normal and abnormal serum samples were analyzed using the SPIFE Touch Split Beta SPE system and the SPIFE Nexus Split Beta SPE system. Deming regression with 95% confidence intervals and Pearson correlation coefficient are presented below.

n = 45

Slope: 1.005 (0.995 to 1.016)

Intercept: -0.10 (-0.38 to 0.17)

R = 0.99

BIBLIOGRAPHY

- Alper CA. Plasma protein measurements as a diagnostic aid. *New England Journal of Medicine*. 1974;291(6):287-290.
- Tiselius A. A New Apparatus for Electrophoretic Analysis of Colloidal Mixtures. *Transactions of the Faraday Society*. 1937;33:524.
- Ritzmann SE, Daniels JC. Diagnostic Proteinology: Separation and Characterization of Proteins, Qualitative and Quantitative Assays. In: *Laboratory Medicine*. Vol 1. Hagerstown (MD): Harper and Row, Inc.; 1979.
- Tietz NW, ed. In: *Textbook of Clinical Chemistry*. Philadelphia (PA): WB Saunders Company; 1986:579-582.
- Ritzmann SE, ed. *Protein Abnormalities, Volume 1. Physiology of Immunoglobulins: Diagnostic and Clinical Aspects*. New York (NY): Allen R. Liss; 1982.
- Keren DF. *Protein Electrophoresis in Clinical Diagnosis*. London: Edward Arnold; 2003.
- Chen LYC, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: What a hematologist needs to know. *Haematologica*. 2019;104(3):444-455.
- Hrkal Z, Kuzelová K, Muller-Eberhard U, Stern R. Hyaluronan-binding properties of human serum hemopexin. *FEBS Letters*. 1996;383(1-2):72-74.
- Lakshminarayanan R, Li Y, Janatpour K, Beckett L, Jialal I. Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. *American Journal of Clinical Pathology*. 2007;127(5):746-751.
- Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clinic Proceedings*. 2003;78(1):21-33.
- Mills JR, Murray DL. Identification of friend or foe: The Laboratory Challenge of Differentiating M-proteins from Monoclonal Antibody Therapies. *The Journal of Applied Laboratory Medicine*. 2017;1(4):421-431.
- Keren DF. Therapeutic Complications: A Caveat for M-protein detection. *The Journal of Applied Laboratory Medicine*. 2017;1(4):342-345.
- McCudden CR, Jacobs JFM, Keren D, Caillon H, Dejoie T, Andersen K. Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. *Clinical Biochemistry*. 2018;51:72-79.
- Strobel SL. The incidence and significance of pseudoparaproteins in a community hospital. *Ann Clin Lab Sci*. 2000;30(3):289-294.

For Sales, Technical and Order Information and Service Assistance, call 800-231-5663 toll free.

Helena Laboratories warrants its products to meet our published specifications and to be free from defects in materials and workmanship. Helena's liability under this contract or otherwise shall be limited to replacement or refund of any amount not to exceed the purchase price attributable to the goods as to which such claim is made. These alternatives shall be buyer's exclusive remedies.

In no case will Helena Laboratories be liable for consequential damages even if Helena has been advised as to the possibility of such damages.

The foregoing warranties are in lieu of all warranties expressed or implied including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose.



1530 Lindbergh Dr.
Beaumont, Texas USA 77707

Pro. 275
10/22(3)